[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AIM: Investigate wether there are differences in the parasympathetic nervous system in Parkinsons patients compared to controls.

MATERIALS AND METHODS: We use the tracer \[11C\]donepezil to image the parasympathetic nervous system. The Investigators will include 20 Parkinsons patients and 20 healthy controls aged 40-80 in our study. The participants will receive a careful medical examination, including a neurological examination, as part of the inclusion process. The subjects also have an MRI scan of the brain. Then PET/CT scans with \[11C\]donepezil are conducted - once for the upper abdominal region and once for the head region. For evaluating the function of the parasympathetic nervous system gastric emptying time, heart rate variability and salivary flow will be measured. These measureless will be correlated to the PET findings.

PERSPECTIVES: The study will potentially result in the development of a PET ligand for imaging the parasympathetic nervous system. This will have applications for research in Parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic nervous system is involved

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System

NCT01877538

Parkinson's Disease

COMPLETED

PharmacoMRI of Parkinson Disease

NCT01528592

Parkinson's Disease

COMPLETED NA

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

NCT00404170

Parkinson Disease

COMPLETED PHASE2

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819

Parkinsonian Syndrome

COMPLETED PHASE2

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

NCT00132626

Parkinson's Disease Parkinsonian Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's patients

Participants with Parkinson's Disease

[11C]donepezil PET

Intervention Type OTHER

Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil

Healthy Controls

Healthy participants

[11C]donepezil PET

Intervention Type OTHER

Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.